Investing.com - Aslan Pharma ADR reported on Wednesday first quarter earnings that missed analysts' forecasts and revenue that was inline with expectations.
Aslan Pharma ADR announced earnings per share of $-0.19 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.16 on revenue of $0.00.
Aslan Pharma ADR shares are down 37.86% from the beginning of the year and are trading at $0.696 , down-from-52-week-high.They are under-performing the Nasdaq which is down 19.78% from the start of the year.
Aslan Pharma ADR shares gained 1.98% in intra-day trade the report.
Aslan Pharma ADR follows other major Healthcare sector earnings this month
Aslan Pharma ADR's report follows an earnings beat by J&J on April 19, who reported EPS of $2.67 on revenue of $23.43B, compared to forecasts EPS of $2.59 on revenue of $23.62B.
UnitedHealth had beat expectations on April 14 with first quarter EPS of $5.49 on revenue of $80.15B, compared to forecast for EPS of $5.36 on revenue of $78.73B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar